0A3S Stock Chart & Stats
$9.46
-$0.24(-3.11%)
At close: 4:00 PM EDT
$9.46
-$0.24(-3.11%)
Day’s Range― - ―
52-Week Range$6.16 - $11.97
Previous CloseN/A
Volume32.31K
Average Volume (3M)92.18K
Market Cap
$1.69B
Enterprise Value$1.13K
Total Cash (Recent Filing)$719.34M
Total Debt (Recent Filing)$295.60M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Nov 05, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.52
Shares Outstanding164,945,720
10 Day Avg. Volume156,406
30 Day Avg. Volume92,179
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-8.52
Price to Sales (P/S)0.97
P/FCF Ratio-4.35
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.67Price Target Upside55.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.64
Revenue Forecast (FY)$371.31M
Bulls Say, Bears Say
Bulls Say
Proprietary Vaccine PlatformThe recombinant nanoparticle and Matrix-M platforms provide a defined technological foundation for developing protein-based vaccines across infectious diseases. This creates potential for repeat use of core capabilities beyond one product, supporting longer-term research productivity and commercialization opportunities.
Strong Gross Margin CapabilityA strong gross margin indicates that Novavax’s vaccine products can retain meaningful economics after direct production costs. If commercial demand and operating execution stabilize, this margin profile could provide a foundation for rebuilding profitability and funding development activity.
Demonstrated Earnings CapacityThe 2025 results show that Novavax has previously converted substantial vaccine revenue into operating and net profit. Although performance later weakened, that demonstrated earnings capacity supports the case that improved commercial execution could materially enhance future financial results.
Bears Say
Revenue Contraction And LossesThe sharp TTM revenue decline and return to losses indicate that recent commercial performance has not been sustained. Persistent contraction would reduce resources available for research, commercialization, and debt obligations, while making future earnings more dependent on renewed product demand or partnerships.
Persistent Cash BurnMulti-year negative operating and free cash flow shows that the business is currently consuming cash rather than self-funding operations. Continued burn can increase dependence on external financing and restrict investment flexibility, particularly while revenue and profitability remain volatile.
Negative Stockholders’ EquityA persistent equity deficit weakens the balance-sheet cushion available to absorb operating setbacks and limits financial flexibility. Even with moderate absolute debt, structurally high leverage relative to negative equity can increase reliance on liabilities and constrain capital-allocation choices.
Novavax News
0A3S FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest share price was $6.16 and its highest was $11.97 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is $1.69B.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Nov 05, 2026 which is in 59 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Aug 06, 2026. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.38 by $0.06.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -0.23.
How many shares outstanding does Novavax have?
Novavax has 164,945,720 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.38. Following the earnings report the stock price went down -0.654%.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in GB:0A3S
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novavax Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.67 (55.04% Upside)
$14.67 (55.04% Upside)
Blogger Sentiment
Bullish
GB:0A3S Sentiment 96%
Sector Average 60%
Sector Average 60%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.19%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-28.50%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Novavax
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
0A3S Company Deck
0A3S Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong strategic progress: rapid expansion of partner collaborations, material partner-driven revenue growth, improved cash position and meaningful reductions in operating costs. Management showcased encouraging preclinical data (notably for a prioritized C. difficile asset) and reiterated 2026 guidance while outlining a credible path to non-GAAP profitability by 2028. Near-term challenges include a large YoY revenue decline driven by a prior-period noncash item, modest direct product sales, continued reliance on partners to convert MTAs to licensed programs and some near-term expense support for partners. On balance, the highlights—particularly partnership momentum, partner-revenue growth, cash runway and cost reductions—substantially outweigh the lowlights, though execution and timing risks remain.View all GB:0A3S earnings summaries0A3S Stock 12 Month Forecast
Average Price Target
$14.67
▲(55.04% Upside)
Technical Analysis
Vir Biotechnology
―
Oric Pharmaceuticals
―
―
AbCellera Biologics
―
Sana Biotechnology
―